Engineered donor cells take aim at Hard-to-Treat cancers

NCT ID NCT07410494

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard treatments. Participants receive either a single-target or dual-target cell product, along with chemotherapy to prepare the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Donor-derived CAR-NK cells (engineered immune cells) with chemotherapy (fludarabine and cyclophosphamide) and IL-2
What this could lead to
If successful, this could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 85 participants, so results may not apply to everyone. Risks include side effects from chemotherapy and the CAR-NK cells, and the treatment may not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • District One Hospital

    RECRUITING

    Beijing, Beijing Municipality, 086-373, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.